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Objectives: We determined whether any individual cancers are increased or decreased in a
cohort of 595 patients with systemic lupus erythematosus (SLE) followed for up to 32 years at
the University College London Hospitals Lupus Clinic, looking for any associated clinical or
serological factors and the prognosis after cancer diagnosis. Methods: We undertook a careful
retrospective review of the medical records and identified all individuals diagnosed with
cancer. For controls, we selected three other patients in the cohort who had not developed
cancer, carefully matched for age, sex, ethnicity and disease duration, to determine if any
obvious differences emerged in a nested case-control design. Results: Thirty-three patients
developed cancer after being diagnosed with SLE. There was a statistically insignificant
small increase in overall cancer risk, standardized incidence ratios (SIRs) 1.05 (95% CI
0.52–1.58) and increased SIRs for cervical, prostate, anal and pancreatic cancers and reduc-
tion in breast cancer SIRs.
Haematological and musculoskeletal manifestations, anticardiolipin and antithyroid globu-
lin antibodies were found to be positively associated with cancer risk in multivariate analysis.
There was no drug, dose or duration was associated with cancer risk. There was a reduction in
survival with a cancer fatality rate of 84.2% (p<0.0001). Conclusion: We found a very small
but statistically insignificant increased cancer risk with reduction in survival. Whereas some
cancers appear to be more common in SLE, notably prostate and cervical cancer, others,
particularly breast cancer, are less frequent. Multiple clinical and serological factors are
involved in the increased risk of malignancy in SLE. No drug dose or duration effect was
identified. Lupus (2013) 22, 919–927.
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Introduction
Over the past 50 years the survival of systemic
lupus erythematosus (SLE) patients has improved,
with rates improving from less than 50% at ﬁve
years in 1955 to over 92% at 10 years.
1
This improvement is attributed to better and
earlier diagnosis, optimized management of disease
and prevention of organ damage. Despite these
advances in care, the life expectancy of patients
with SLE remains lower than the general
population.
2 This reduction is attributed to the
fact that as care improves, more chronic factors
(cardiovascular morbidity, malignancy and
increased risk of infections) now contribute to the
long-term sequelae of the disease and its
management.
3,4
Links between malignancy and autoimmune
rheumatic disease have focused on lymphoma,
especially Non-Hodgkin’s lymphoma (NHL).
5
However, is there really an overall increased risk
of malignancy in SLE? Various clinical series and
cohort studies have sought to clarify the issue; some
have shown an increased risk
6–8 whilst others have
not.
9,10 In the most comprehensive report so far,
the Systematic Lupus International Collaborating
Clinics (SLICC) group, in an international multi-
centre cohort study involving 9547 patients,
reported an increased risk of malignancy in SLE,
especially NHL.
11
In spite of various attempts, the question of
whether medication inﬂuences this risk is
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arthritis (RA) and post-organ transplant have con-
ﬁrmed the increased risk of malignancy associated
with immunosuppressive drugs, but this still
remains inconclusive in patients with SLE.
12–14
There are several hypotheses about the patho-
genesis of malignancy in SLE, including medication
use, interaction with viruses, disordered immuno-
surveillance, and coexistence of other diseases like
Sjo ¨ gren’s and RA that have a known association
with malignancy.
15–19
To explore the possible pathogenic risk factors
further, we undertook a detailed analysis within the
University College London Hospitals (UCLH)
lupus cohort of 36 patients who have developed
cancer, analysing the disease manifestations, auto-
antibody proﬁle, associated diseases and in particu-
lar, the steroid and immunosuppressive regimens
they were treated with. We have taken advantage
of the unusually long-term follow-up (up to 32
years) and data recording in this cohort to estab-
lish, as accurately as possible, the relative risk of
cancer and the speciﬁc types of malignancy after
the diagnosis of SLE. We were particularly inter-
ested to discover whether the increased incidence, if
any, is associated with the clinical characteristics of
patients or the type of immunosuppressive therapy
and if so, what cumulative dose or time interval of
exposure is associated with this risk, and to review
the prognosis and cause of death in the cohort after
developing cancer.
Methods
Approval for this study was obtained from the
UCLH Research and Development Committee.
Study population
The UCLH Lupus Clinic has a cohort of 595 SLE
patients diagnosed and followed up for up to 32
years, i.e. from 1978 to the end of December
2010. All patients followed up over time are entered
into the cohort when they fulﬁl the American
College of Rheumatology (ACR) revised classiﬁca-
tion criteria for SLE.
20
Selection of cases and controls
We identiﬁed all 36 individuals who have developed
cancer after being diagnosed with SLE and selected
as controls three individuals for each of the ‘‘cancer
cases’’ who have SLE, but have not developed
cancer in the cohort during this period
of observation. The controls were carefully
matched for age, sex, ethnicity and disease dur-
ation. These control patients had disease duration
within ﬁve years of their matched index case.
No cases of drug-induced, discoid lupus or
undiﬀerentiated autoimmune disease were included
in this cohort study. However, cases of SLE meet-
ing the ACR criteria, who have met standard cri-
teria for other autoimmune conditions, were
included to examine the possible links with con-
comitant diseases, such as Sjo ¨ gren’s syndrome,
which has been found to increase cancer risk.
Case definition
Cancers were identiﬁed through the hospital med-
ical records and conﬁrmed by histological or aut-
opsy reports. Cancer cases had been identiﬁed by
clinical features suggestive of cancer and incidental
ﬁndings, and some cases of cervical cancer were
identiﬁed through a routine screening programme
oﬀered to all women in the United Kingdom (UK)
in the relevant age group.
The health system in the UK requires patients to
have family practitioners, and regular correspond-
ence between the practitioner and the lupus clinic
helps to guarantee that any malignancy identiﬁed
by either ‘‘side’’ will be communicated eﬀectively.
As part of the malignancy studies conducted by the
SLICC group, we have been in contact with the UK
National Cancer Registry to check for any cancer
cases our SLE patients reported to them. Thus it is
most unlikely that any case of malignancy was
missed in our cohort.
Index date
The follow-up period was from the date of diagno-
sis of SLE till the last review date or death or 31
December 2010. (Disease duration was ascertained
as the time of diagnosis of SLE, i.e. when the
patients reach their fourth lupus criterion, to the
date of their cancer diagnosis.)
We undertook retrospective analysis of the med-
ical records of the patients, collecting data on age,
sex, date of diagnosis of SLE and cancer, duration
between cancer and SLE diagnosis, type of cancer
diagnosed, time to death if relevant, clinical mani-
festations, autoantibody proﬁle, smoking history,
nonsteroidal anti-inﬂammatory drug (NSAID)
use, immunosuppressive drug use- type, cumulative
dosage and duration of use and other concomitant
conditions.
Patients were generally deemed to have
been ‘‘on’’ individual immunosuppressive drugs
if they had been taking them for a minimum of
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Lupusthree months. Anti-double-stranded DNA (anti-
dsDNA) and extractable nuclear antibodies
(ENA) were assessed using a Euro Diagnostica
enzyme-linked immunosorbent assay (ELISA).
Anti-dsDNA antibodies were also tested by the
immunoﬂuorescent Crithidia assay. Patients were
considered to be anti-dsDNA antibody positive if
they were ever Crithidia positive or had an ELISA
result more than twice the upper limit of normal on
two occasions. Complement component levels were
measured by laser nephelometry. We have used the
same anti-DNA, anti-ENA and C3 assays for over
20 years and, utilizing stored serum samples for
patients who lived (and in some cases died), we
have tested samples obtained early in the course
of disease with the current methods utilizing
stored samples so that we can genuinely say that
all of our patients have had their serum tested by
the same methodology. We used results obtained
around the period they were classiﬁed as fulﬁlling
the ACR criteria for SLE for consistency.
Use of drugs and immunosuppressive agents
from time of SLE diagnosis up to the time of the
diagnosis of cancer (ever or never, cumulative dose
over time and duration of use) was calculated for
cases with cancer and up to the deﬁned end of
follow-up for those without.
To assess the damage accrued, we used the
SLICC/ACR damage index. Though not a measure
of disease activity, it has been shown to reﬂect
cumulative disease activity over time.
21
Statistical analysis
Statistical Packages for Social Sciences version 18.0
(SPSS Inc, Chicago, IL, USA) was used for data
entry and analysis. Standardized incidence ratios
(SIRs, the quotient of observed to expected can-
cers) were also calculated for males and females,
overall cancer and individual cancers using the
Thames Cancer Registry’s ﬁve-year annualized
age and gender-speciﬁc cancer rates per 100,000
population for the southeast of England
22 and
their 95% conﬁdence intervals (CIs) were attained
by using observed cases as a Poisson variable and
its associated interval from formulae based on the
Poisson distribution.
23 The expected number of
malignancies (E) was calculated as the sum of all
person-years at risk in the age group (i) from the
cohort study (ni) multiplied by the age- and sex-
speciﬁc cancer rates for the South East of
England in the age group i (Ri) using the expres-
sion E¼
P
(ni) Ri.
The relation between cancer and the probable
risk factors was explored by comparing clinical
and serological characteristics of patients who
developed malignancies and those who had not
developed malignancies in a nested case-control
design. Case fatality rate was calculated as a per-
centage of deaths in the cohort with malignancy
over total number of cases in that cohort through
their disease course and cancer fatality rate as
deaths directly due to cancer over deaths in the
cohort with malignancy. With development of
cancer (cases) as the dependent variable and demo-
graphic characteristics, clinical and serological fac-
tors as independent variables, univariate analysis
was conducted using the 2 2 contingency table
for each of the independent variables to determine
any association between them and the development
of malignancy. Following the univariate analysis,
variables that attained a p value<0.1 were retained
for multivariate analysis. However, as few variables
met the criteria for inclusion into the multivariable
analysis (i.e. p value<0.1), all variables were
included into the model. A backward elimination
procedure form of the logistic regression model was
used to calculate the odds ratio (ORs) and 95% CIs
for the risk of cancer development.
Results
A total of 595 SLE patients were followed up until
31 December 2010. Of these patients, 81 died and a
further 58 were no longer being followed up in our
clinic. Eight have been followed up in other (not-
ably renal) clinics in our hospital and 50 have
moved away, some to be followed up in other
UK clinics and others overseas.
Out of the 595 patients, we estimate that we have
lost complete contact, long-term, with only 25
patients. In this cohort analysis we did not get com-
plete data for only one patient and could not com-
pletely match all the male cancer cases. A total of
37 malignancies were diagnosed in 36 patients.
Four of these were diagnosed in patients before
SLE onset. One patient was diagnosed with two
diﬀerent malignancies, one before the onset and
one afterwards. Those malignancies before the
onset of SLE were eliminated from the analysis,
which was therefore undertaken on 33 patients.
Demographic characteristics
Thirty females and three males developed cancer
after diagnosis of SLE (Table 1). The mean dur-
ation of follow-up was 14.7 years. Total person-
years of follow-up was 8910.51, and the mean age
at diagnosis of SLE and cancer was 33.5 (SD 12.7)
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Lupusyears and 50.3 (SD 14.8) years, respectively. The
mean time interval between diagnosis of SLE and
cancer was 16.4 (SD 9.73) years. The majority of
patients were Caucasian (90.9%) and most cancer
cases occurred in Caucasians. Nineteen (57.6%) of
the 33 cancer patients died during the follow-up
period, with a cancer fatality rate of 84.2%; signiﬁ-
cantly more people died from cancer than noncan-
cer causes (p<0.0001).
There was a small but statistically insigniﬁcant
increase in overall cancer risk, SIR 1.05 (95% CI
0.52–1.58).The most frequently occurring cancers
Table 1 Univariate analysis with odds ratio (OR), 95% confidence intervals (95% CIs) and p values comparing clinical,
serological characteristics and medical treatment of SLE cancer cases and controls
Demographic Characteristics Cases n¼33 (%)
Controls
n¼94 (%) OR 95% CIs p value<0.05
Clinical features
Mucocutaneous 30 (90.9%) 73 (77.7%) 2.9 (0.8, 10.4) 0.12
Musculoskeletal 2 (6.1%) 1 (1.0 %) 5.9 (0.5, 67.7) 0.17
Neuropsychiatric 7 (21.2%) 23 (24.5%) 0.8 (0.3, 2.2) 0.81
Cardio respiratory 7 (21.2%) 23 (24.5%) 0.8 (0.3, 2.2) 0.81
Gastrointestinal 0 (0%) 2 (2.1%) – – NA
Ophthalmic 14 (42.4%) 53 (56.4%) 0.6 (0.3, 1.3) 0.22
Renal 15 (45.5%) 34 (36.2%) 1.5 (0.6, 3.3) 0.41
Haematological 20 (60.6%) 83 (88.3%) 0.2 (0.1, 0.5) 0.001
Immunological profile
Antinuclear antibodies 33 (100%) 90 (97.9%) 1.4 (1.2, 1.5) 0.39
Anti-dsDNA antibodies 18 (54.5%) 61 (64.9%) 0.7 (0.3, 1.5) 0.30
Rheumatoid factor 11 (33.3%) 28 (29.8%) 1.2 (0.5, 2.8) 0.80
Anti-Sm antibodies 3 (9.11%) 12 (12.8%) 0.4 (0.1, 2.1) 0.35
Anti-RO antibodies 7 (21.2%) 29 (30.9%) 0.6 (0.2, 1.5) 0.37
Anti-La antibodies 6 (18.2%) 9 (9.6%) 2.1 (0.7, 6.4) 0.21
Anti-RNP antibodies 9 (27.3%) 23 (24.5%) 1.2 (0.5, 2.8) 0.82
Low C3 11 (33.3%) 44 (46.8%) 0.6 (0.3, 1.3) 0.22
Lupus anticoagulant 7 (21.2%) 13 (13.8%) 2.2 (0.8, 5.9) 0.16
Anticardiolipin antibodies 9 (27.3%) 33 (35.9%) 0.4 (0.2, 1.2) 0.07
Coombs positivity 6 (18.2%) 25 (26.6%) 0.6 (0.3, 1.6) 0.48
Antithyroid globulin antibodies 2 (6.1%) 25 (26.6%) 0.2 (0.4, 0.8) 0.01
Smoking (ever) 15 (45.5%) 44 (46.8%) 0.9 (0.4, 2.1) 0.92
NSAID use 6 (19.4%) 24 (25.8%) 0.6 (0.2, 1.7) 0.48
Aspirin use 13 (41.9%) 35 (37.6%) 1.2 (0.5, 2.7) 0.68
Steroid use 25 (80.6%) 74 (78.7%) 1.3 (0.5, 3.5) 0.41
Hydroxychloroquine 24 (77.4%) 67 (71.3%) 1.1 (0.4, 2.6) 1.00
Azathioprine (AZA) 15 (46.9%) 45 (47.9%) 0.9 (0.4, 2.1) 1.00
Methotrexate (MTX) 2 (6.5%) 8 (8.5%) 0.8 (0.2, 4.1) 1.00
Cyclophosphamide (CYC) 8 (25.8%) 24 (25.5%) 0.9 (0.4, 2.5) 1.00
Cyclosporine 1 (3.0%) 3 (3.2%) 0.9 (0.1, 16.4) 1.00
Mycophenolate mofetil (MMF) 2 (3.0%) 13 (13.8%) 0.4 (0.1, 1.8) 0.35
Rituximab 0 (0%) 19 (20.2%) – – NA
Hypothyroid 2 (6.5%) 12 (12.8%) 0.4 (0.1, 2.1) 0.35
Hyperthyroid 0 (0%) 4 (4.3%) – – NA
Rheumatoid arthritis 1 (3.0%) 2 (2.1%) 1.4 (0.1, 16.4) 1.00
Undifferentiated autoimmune rheumatic disease 0 (0%) 0 (0%) – – –
Sjo ¨ gren’s 3 (9.1) 9 (9.6) 0.9
Diabetes 2 (6.5%) 5 (5.3%) 1.1 – –
Sarcoidosis 0 (0.0%) 1 (1.1%) – – –
Myositis 0 (0.0%) 2 (2.1%) – – NA
Liver cirrhosis 0 (0%) 2 (2.1%) – – NA
Antiphospholipid syndrome 1 (3.0%) 9 (9.6%) 0.3 (0.0, 2.4) 0.45
Myasthenia gravis 0 (0.0%) 0 (0.0%) – – NA
Scleroderma 1 (3.0%) 1 (1.1%) 2.9 (0.8, 47.8) 0.45
Other autoimmune disease 15(45.5%) 40 (42.6%) 1.1 (0.5, 2.5) 0.84
SLICC damage 26 (47.3%) 29 (52.7%) 0.12 (0.0,0.36) 0.0001
Abbreviations: n: number; NA; not analysed; SLE: systemic lupus erythematosus; NSAID: nonsteroidal anti-inflammatory drug; anti-dsDNA:
anti-double-stranded DNA; SLICC scores: Systemic Lupus Erythematosus International Collaborating Clinic scores.
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Lupusfollowing the diagnosis of SLE were breast and
lung cancers, with ﬁve cases each (15.2%).
Using the South East England age standardized
cancer rates, there were statistically increased SIRs
for cervical, prostate, anal and pancreatic cancers.
The age standardized incidence rates for the other
cancers were not available forcomparison (Table 2).
The majority of cases, nine (27.3%), were in the
30- to 39-year age group, and 69.7% were>40
years. Malignancy was diagnosed in two patients
less than a year after SLE diagnosis and both
cases were breast cancers in patients less than 50
years of age (Table 3).
Univariate analysis found a statistically signiﬁ-
cant association between cancer and antithyroid
globulin antibodies, haematological manifestations
and SLICC damage scores (Table 1).
As few of the variables met a p value cut-oﬀ
point of 0.1 for inclusion into the model, all vari-
ables were entered into the multivariate analysis
model. There was a statistically signiﬁcant positive
association found with musculoskeletal 7.94 (95%
CI 1.68–37.82) and haematological manifestations
4.64 (95% CI 2.05–10.06), anticardiolipin 9.17
(95% CI 2.73–30.78), and antithyroid globulin anti-
bodies 2.91 (95% CI 1.0–12.64).
None of the medications used showed an associ-
ation with cancer risk, and further analysis showed
no critical dose or duration eﬀect for cyclophospha-
mide use and no association with cancer.
There was no clear association between duration
of disease and susceptibility to either a solid or
haematological malignancy. Seventy-ﬁve per cent
of cases that occurred less than ten years after
SLE diagnosis were solid tumours and 25% were
haematological, namely Hodgkin’s lymphoma and
one large granular lymphocytic (LGL) leukaemia.
Two lung cancers occurred less than ten years after
SLE onset, and for the haematological malignan-
cies, 50% of patients were younger than 50 years at
diagnosis and the other half older than 50 years. All
cancers occurring after 20 years of disease duration
were solid tumours. Cumulative survival fell in the
ﬁrst ﬁve years after a cancer diagnosis with a very
sharp drop in the ﬁrst year; survival at ﬁve years
was less than 20%; at 20 years less than 10%; and
almost 0% at 22 years. Only three of the controls
died, two from ischemic heart disease and one com-
mitted suicide. Those<50 years when they devel-
oped cancer after SLE diagnosis tended to die
faster than the 50-plus year groups (Figure 1).
Discussion
Determining accurate cancer risk in a disease like
SLE, which nowadays may aﬀect patients for
Table 2 Cancers observed and expected in SLE cancer
patients with standard incidence ratios (SIR) and 95% confi-
dence intervals (95% CIs) compared to the general population.
Risks for other malignancies were not calculated as there were
no comparable data for the general population
Characteristics Observed Expected SIR 95% CIs
All cancers 33 31.5 1.05 0.52–1.58
Female 30 29.0 1.03 0.66–1.40
Male 3 3.0 1.00 0.29–1.06
Lung cancer 5 2.9 1.72 0.97–2.47
Breast cancer 5 10.5 0.48 0.35–0.64
Cervical cancer 2 0.5 4.00 3.50–4.50
Anal cancer 2 1.1 1.80 1.48–2.12
Prostate cancer 3 0.7 4.29 1.09–10.24
Non-Hodgkin’s
lymphoma (NHL)
1 1.1 0.91 0.87–0.95
Pancreatic cancer 1 0.7 1.43 1.32–1.54
Hodgkin’s disease 2 NR NR NR
Vulval cancer 1 NR NR NR
Cholangiocarcinoma 1 NR NR NR
Appendiceal cancer 1 NR NR NR
Large granular lymphocytic
leukaemia
1N R N R N R
Cancer of the cheek 1 NR NR NR
Gall bladder cancer 1 NR NR NR
Cancer of the tongue 1 NR NR NR
Skin cancer 2 NR NR NR
Bowel cancer 2 NR NR NR
Hepato-biliary cancer 1 NR NR NR
SLE: systemic lupus erythematosus; NR: not recorded; p value<0.05.
Table 3 SLE cases with cancer and their observed cancer
frequencies for various age ranges and duration between SLE
and cancer diagnosis
Age range in years for
SLE cases with cancer
Observed cancer
frequency
0–20 0
20–29 1
30–39 9
40–49 7
50–59 7
60–79 7
> 80 2
Duration between SLE diagnosis
and cancer in years
Observed cancer
frequency
< 12
1–5 2
6–10 8
11–15 5
16–20 4
> 20 12
SLE: systemic lupus erythematosus.
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Lupusseveral decades, is very challenging. The SLICC
study
11 captured cancers reported in almost
10,000 patients. While the denominator is most
impressive (and our group was a contributor to
this eﬀort), given that over 23 centres were involved
it is inevitable that variation in the quality and
completeness of data must have occurred.
Furthermore, the mean duration of follow-up was
only eight years, limiting the ability of the study to
link long-term immunosuppressive use to cancer
development. The SLICC study was also, for
understandable reasons, unable to comment on
any cancer association with lupus serology, disease
activity or damage.
The present study has attempted to address some
of these problems. We have followed up almost 600
SLE patients for up to 32 years as assiduously as
possible, losing only 25 patients to any kind of
long-term follow-up. Thus mean duration of our
patient follow-up is almost twice that of the
SLICC study. We have reported on links to sero-
logical abnormalities (using the same assays
throughout the study) damage and indirectly
(albeit incompletely) disease activity. The nested
case-control study design in our study is advanta-
geous in that the estimates derived in this way
should be virtually identical to a full cohort ana-
lysis, and if associations are found this could be
explored further in cohort studies.
The main ﬁndings in this study are a small but
statistically insigniﬁcant overall increased risk of
cancer in SLE in contrast to previously reported
studies of increased cancer,
6–8,11,24–28 with a par-
ticular increase in prostate, anal, pancreatic and
cervical cancers but smaller than expected numbers
of breast cancer.
In the SLICC cohort, a reduced incidence of
endometrial and probably breast and ovarian can-
cers were found. Though breast cancer cases were
the highest number of cancer cases recorded
together with lung cancer in our cohort, there was
no increased risk compared to the general popula-
tion. A recent study exploring whether risk alleles
of the single-nucleotide polymorphisms (SNPs)
inﬂuencing the risk of acquiring SLE may be oﬀer-
ing some protection against breast cancer found
only two out of the 17 SLE SNPs studied to be
negatively linked with breast cancer in the
genome-wide association studies (GWAS) data.
The signiﬁcance of this is, however, not clear and
is being explored further, but may help to explain
the lowered risk of breast cancer in SLE patients.
29
Figure 1 Kaplan Meier survival function curve: survival curve for cancer cases comparing ages<50 and >50years.
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LupusSome previous studies have reported an
increased risk of lung cancer with histological dis-
tribution comparable to the general population.
30
We found a similar distribution, but a much higher
incidence of adenocarcinomas (60%, as compared
to 30%–40%), including one case of bronchoalveo-
lar adenocarcinoma, small cell carcinoma (20%)
and one non-small cell carcinoma (20%).Though
there was an increase in lung cancer cases compared
to the general population, it was not statistically
signiﬁcant. All our cases of lung cancer were smo-
kers (100%); smokers in the cases and controls
were similar, 45.5% and 46.8%, respectively, a
higher overall estimate than previous studies of
smoking in lupus patients of 17%–21%. Three
out of ﬁve patients had been exposed to immuno-
suppressive therapy, two to azathioprine and one to
methotrexate. All cases died, with four out of the
ﬁve cases doing so less than a year and the other
case after one year. Five-year lung cancer survival
in the general population is estimated at 7%–9%,
with 50% dying within four months of diagnosis.
31
One of our cases had ﬁbrosing alveolitis, which has
also been linked to lung cancer.
32–34 Some studies
show a decreased risk of prostate cancer in SLE,
with low hypoadrenergic states in men with SLE
and genetic factors as possible risks;
35 in contrast,
we found an increased risk of prostate cancer.
We did not ﬁnd an increase in haematological
malignancies, notably the lymphomas, as other stu-
dies have reported. An interesting postulation is
whether the use of rituximab, which is a treatment
for B cell lymphoma, may be causing a reduction in
lymphoma incidence as reported in a study in
Sjo ¨ gren’s syndrome where it reduced risk of
mucosa-associatedlymphoidtissue(MALT)lymph-
omas.
36 It would be interesting to examine data
from other cohorts to see if the frequencies of diag-
nosed lymphomas have reduced in recent times.
Multivariate analysis suggested a positive associ-
ation between clinical and serological manifest-
ations, notably musculoskeletal, haematological
manifestations, anticardiolipin and antithyroid
globulin antibodies and cancer risk. The strength
of positive association factors was relatively weak
with wide CIs, probably due to the small sample
size, and larger cohorts studies are needed to con-
ﬁrm these ﬁndings.
It would have been optimal to relate the disease
activity over time to cancer risk, using tools such as
the British Isles Lupus Assessments Groups
(BILAG) disease activity score. However, we did
not have suﬃcient data on some patients, notably
those followed up for greater than 20 years and
therefore could not measure these scores
retrospectively.
We obtained our calculation for expected cancers
based on person-years of risk calculations, meaning
we considered their contribution to development of
cancer only up to the time of development of the
cancer and not after the disease had developed; we
were limited in calculating observed rates for each
year that they developed cancer though that would
havebeenamoreaccuratemeasure.Serologicaltests
and complement levels were also calculated at a
point in time rather than over a period.
Previous studies have linked damage accrual in
SLE patients, clearly associated with prior activity
with cancer risk.
11,37,38 Inour study,SLICC damage
scores were found to be associated with cancer risk
in univariate but not multivariate analysis.
However, positive anti-dsDNA antibody status
and low C3 levels, markers that are generally
regarded as useful measures of activity, were not
found to be statistically signiﬁcantly associated
with cancer risk in this study. The association with
damage scores though supports the notion that dis-
ease activity (and hence eventual damage accrual)
may be one of the major determinants of cancer
risk development as has been found in RA rather
than the use of immunosuppressive drugs.
39 Low
C3 (hazard ratio (HR) ¼ 6.18, 95% CI 1.57–
24.22) was a signiﬁcant predictor of lymphoproli-
ferative disease and premature death in patients
with primary Sjo ¨ gren’s.
40,41
Haematological aberrations, usually manifesting
as cytopaenias, is seen in both SLE and some malig-
nancies, typically lymphoproliferative. These cyto-
paenias form part of the ACR classiﬁcation criteria,
but on occasion may be paraneoplastic phenomena.
However, only two of our SLE patients developed
cancers in the ﬁrst two years following SLE diagno-
sis. Thus in these patients cytopaenias could have
been related to the development of malignancy
rather than SLE. We did not examine the individual
contributions of the various cytopaenias.
There have been reports of excess autoantibodies
in the sera of patients with cancer compared to
controls, especially lymphomas, including anti-
dsDNA, antiribonucleoprotein (anti-RNP) and
anti-Smith (anti-Sm) antibodies. These data suggest
these antibodies may be related to cancer develop-
ment or possibly aging. In our cohort these diag-
nostic tests were detected prior to the patients’
cancer diagnosis and thus are unlikely to be the
result of their cancer.
The mechanism by which antithyroid globulin
antibodies may be linked to cancer risk is unknown.
Some studies indicate a signiﬁcant association
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autoimmune thyroid disorders and some report an
increased incidence of breast cancer in patients with
Hashimoto’s thyroiditis.
42 An association of anti-
phospholipid antibodies (aPL) and cancer has been
sought. Recent ﬁndings imply an increased preva-
lence of certain cancers in aPL-positive patients;
thus, a thorough investigation for an occult malig-
nancy is encouraged in these patients. In addition,
several studies reported on elevated levels of aPL
antibodies in various malignancies.
43
Relatively few patients were taking prescribed
NSAIDs. This could have been because their use
is not really encouraged in SLE patients. NSAID
use has been in found in several studies to be asso-
ciated with reduced cancer risk, especially colonic
cancers and breast cancers and in patients with RA,
contrary to the ﬁndings in this study.
44–46
There appears to be a reduction in survival in
SLE patients compared to those without cancer
and earlier mortality if diagnosed at a younger
age. This is a cause for concern, especially with
the higher risk found of cancers associated with
high mortality like lung cancer, as it diminishes
the good results achieved in improving the morbid-
ity and mortality in SLE.
Mortality from cancer has been reported to be
higher in lupus patients than in the general popu-
lation; previous studies showing increased mortal-
ity from lung cancers and NHL support the
ﬁndings from this study.
3,47
Conclusion
Our results show a statistically insigniﬁcant, small
overall increased risk of cancer in SLE patients, but
an interesting dichotomy that some cancers appear
to be more common, especially prostate and cervical
cancers, but with reduction in breast cancer rates.
Increased disease activity may be implicated in this
risk. The clinical and serological proﬁle of patients
needs to be explored in more detail in future studies
to determine the possible pathological pathways in
which it predisposes some patients to increased
cancer risk. The role of drugs, especially cyclophos-
phamide, is a subject of concern, but its role in
cancer risk in SLE is not deﬁnite.
Clinical implications
. Multi-factorial causes are involved in the
increased risk of malignancy in systemic lupus
erythematosus (SLE).
. There is increased mortality from cancers and
lung cancer in particular.
. Lung, prostate and cervical cancers are
increased; others, notably breast cancers, are
less frequent.
Funding
This research received no speciﬁc grant from any
funding agency in the public, commercial, or not-
for-proﬁt sectors.
Conflict of interest statement
Dr Dey’s fellowship training was partly supported
by a training bursary from the European League
Against Rheumatism (EULAR).
References
1 Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality
in systemic lupus erythematosus during a 10-year period: A com-
parison of early and late manifestations in a cohort of 1,000
patients. Medicine 2003; 82: 299–308.
2 Ward M, Pyun E, Studenski S. Causes of death in systemic lupus
erythematosus. Long-term followup of an inception cohort.
Arthritis Rheum 1995; 38: 1492–1499.
3 Moss K, Ioannou Y, Sultan SM, Haq I, Isenberg DA. Outcome of
a cohort of 300 patients with systemic lupus erythematosus attend-
ing a dedicated clinic for over two decades. Ann Rheum Dis 2002;
61: 409–413.
4 Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality
studies in systemic lupus erythematosus. Results from a single
center. I. Causes of death. J Rheumatol 1995; 24: 1061–1065.
5 Dias C, Isenberg DA. Susceptibility of patients with rheumatic
diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol
2011; 7: 360–368.
6 Pettersson T, Pukkala E, Teppo L, Friman C. Increased risk of
cancer in patients with systemic lupus erythematosus. Ann Rheum
Dis 1992; 51: 437–439.
7 Ramsey-Goldman R, Mattai SA, Schilling E, et al. Increased risk
of malignancy in patients with systemic lupus erythematosus.
J Invest Med 1998; 46: 217–222.
8 Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R,
Jorgen HO. Non-Hodgkin’s lymphoma and other cancers among
a cohort of patients with systemic lupus erythematosus. Arthritis
Rheum 1997; 40: 761–768.
9 Sweeney DM, Manzi S, Janosky J, et al. Risk of malignancy in
women with systemic lupus erythematosus. J Rheumatol 1995; 22:
1478–1482.
10 Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in
systemic lupus erythematosus. Arthritis Rheum 1996; 39:
1050–1054.
11 Bernatsky S, Boivin JF, Joseph L, et al. An international cohort
study of cancer in systemic lupus erythematosus. Arthritis Rheum
2005; 52: 1481–1490.
12 Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB.
Occurrence of neoplasia in patients with rheumatoid arthritis
enrolled in a DMARD registry. The Rheumatoid Arthritis
Azathioprine Registry Steering Committee. J Rheumatol 1991;
18: 809–814.
Cancer complicating SLE – a dichotomy emerging from a nested case-control study
D Dey et al.
926
Lupus13 Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative
cancer and other malignancy in patients with rheumatoid arthritis
treated with azathioprine: A 20 year follow up study. Ann Rheum
Dis 1988; 47: 988–992.
14 London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk
of neoplasia in renal transplant patients. Lancet 1995; 346:
403–406.
15 Mariette X. Lymphomas in patients with Sjo ¨ gren’s syndrome:
Review of the literature and physiopathologic hypothesis. Leuk
Lymphoma 1999; 33: 93–99.
16 Oertel SH, Riess H. Immunosurveillance, immunodeficiency and
lymphoproliferation. Recent Results Cancer Res 2002; 159: 1–8.
17 Boubenider S, Hiesse C, Groupy C, Kriaa F, Marchand S,
Charpentier B. Incidence and consequences of post-transplantation
lymphoproliferative disorders. J Nephrol 1997; 10: 136–145.
18 Bernatsky S, Boivin JF, Joseph L, et al. Prevalence of factors
influencing cancer risk in women with lupus: Social habits, repro-
ductive issues, and obesity. J Rheumatol 2002; 29: 2551–2554.
19 Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y. The dual
association between lymphoma and autoimmunity. Blood Cells
Mol Dis 2001; 27: 750–756.
20 Hochberg MC. Updating the American College of Rheumatology
revised criteria for the classification of systemic lupus erythemato-
sus. Arthritis Rheum 1997; 40: 1725.
21 Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability
of the Systemic Lupus International Collaborating Clinics/
American College of Rheumatology damage index in patients
with systemic lupus erythematosus. Arthritis Rheum 1997; 40:
809–813.
22 Cancer in South East England. Cancer incidence, prevalence, sur-
vival and treatment for residents of South East London in 2008.
London: Thames Cancer Registry, 2010.
23 Breslow NE, Day NE. Statistical methods in cancer research.
Volume II – The design and analysis of cohort studies. IARC.
Sci Publ 1987; 82: 1–406.
24 Bjo ¨ rna ˚ dal L, Lo ¨ fstro ¨ m B, Yin L, Lundberg IE, Ekbom A.
Increased cancer incidence in a Swedish cohort of patients with
systemic lupus erythematosus. Scand J Rheumatol 2002; 31: 66–71.
25 Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the
risk of malignancy. Lupus 2001; 10: 394–400.
26 Parikh-Patel A, White R, Allen M, Cress R. Cancer risk in a cohort
of patients with systemic lupus erythematosus (SLE) in California.
Cancer Causes Control 2008; 19: 887–894.
27 Chen YJ, Chang YT, Wang CB, Wu CY. Malignancy in systemic
lupus erythematosus: A nationwide cohort study in Taiwan. Am J
Med 2010; 123: 1150.e1–1150.e6.
28 Lewis R, Castor CW, Knisley RE, Bole GG. Frequency of neopla-
sia in systemic lupus erythematosus and rheumatoid arthritis.
Arthritis Rheum 1976; 19: 1256–1260.
29 Bernatsky S, Easton D, Dunning AM, et al. Decreased breast
cancer risk in SLE: Can a genetic basis be determined? Arthritis
Rheum 2011; 63: 223–224.
30 Bin J, Bernatsky S, Gordon C, et al. Lung cancer in systemic lupus
erythematosus. Lung Cancer 2007; 56: 303–306.
31 Cancer Research UK. Cancer Statistics key facts, http://www.can-
cerresearchuk.org/cancerstats (2010).
32 Turner-Warwick M, Lebowitz M, Burrows B, Johnson B.
Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980;
35: 496–499.
33 Harris JM, Johnston IDA, Rudd R, Taylor AJ, Cullinan P.
Cryptogenic fibrosing alveolitis and lung cancer: The BTS study.
Thorax 2010; 65: 70–76.
34 Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and crypto-
genic fibrosing alveolitis. A population-based cohort study. Am J
Respir Crit Care Med 2000; 161: 5–8.
35 Bernatsky S, Ramsey-Goldman R, Gordon C, Clarke AE. Prostate
cancer in systemic lupus erythematosus. Int J Cancer 2011; 129:
2966–2969.
36 Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment
in patients with primary Sjo ¨ gren’s syndrome: An open-label phase
II study. Arthritis Rheum 2005; 52: 2740–2750.
37 Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis
of the relationship between disease activity and damage in patients
with systemic lupus erythematosus – a 5-yr prospective study.
Rheumatology (Oxford) 2004; 43: 1039–1044.
38 Chambers S, Allen E, Rahman A, Isenberg D. Damage and mor-
tality in a group of British patients with systemic lupus erythema-
tosus followed up for over 10 years. Rheumatology (Oxford) 2009;
48: 673–675.
39 Baecklund E, Iliadou A, Askling J, et al. Association of chronic
inflammation, not its treatment, with increased lymphoma risk in
rheumatoid arthritis. Arthritis Rheum 2006; 54: 692–701.
40 Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of
death in primary Sjo ¨ gren’s syndrome: A prospective cohort study.
Arthritis Rheum 2004; 50: 1262–1269.
41 Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R,
Jacobsson LT. Lymphoma and other malignancies in primary
Sjo ¨ gren’s syndrome: A cohort study on cancer incidence and
lymphoma predictors. Ann Rheum Dis 2006; 65: 796–803.
42 Turken O, Narin Y, Demirbas S, et al. Breast cancer association
with thyroid disorders. Breast Cancer Res 2003; 5: 110–113.
43 Reinstein E, Shoenfeld Y. Antiphospholipid syndrome and cancer.
Clin Rev Allergy Immunol 2007; 32: 184–187.
44 DuBois RN, Giardiello FM, Smalley WE. Nonsteroidal anti-
inflammatory drugs, eicosanoids, and colorectal cancer prevention.
Gastroenterol Clin North Am 1996; 25: 773–791.
45 Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibupro-
fen, and other non-steroidal anti-inflammatory drugs in cancer
prevention: A critical review of non-selective COX-2 blockade
(review). Oncology Rep 2005; 13: 559–583.
46 Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer
among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;
85: 307–311.
47 Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus
erythematosus. Arthritis Rheum 2006; 54: 2550–2557.
Cancer complicating SLE – a dichotomy emerging from a nested case-control study
D Dey et al.
927
Lupus